These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29088891)

  • 1. Cost-utility of stereotactic radiation therapy
    Leung HWC; Chan ALF
    Oncotarget; 2017 Sep; 8(43):75568-75576. PubMed ID: 29088891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
    Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
    Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
    Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review.
    Wang H; Jin C; Fang L; Sun H; Cheng W; Hu S
    Cost Eff Resour Alloc; 2020; 18():1. PubMed ID: 31938024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.
    Li G; Xia YF; Huang YX; Okat D; Qiu B; Doyen J; Bondiau PY; Benezery K; Gao J; Qian CN
    BMC Cancer; 2021 Aug; 21(1):944. PubMed ID: 34419008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
    Wali AR; Park CC; Brown JM; Mandeville R
    Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.
    Parthan A; Pruttivarasin N; Davies D; Taylor DC; Pawar V; Bijlani A; Lich KH; Chen RC
    Front Oncol; 2012; 2():81. PubMed ID: 22934286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus Proton Therapy for Oropharyngeal Squamous Cell Carcinoma.
    Sher DJ; Tishler RB; Pham NL; Punglia RS
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):875-882. PubMed ID: 29976499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
    Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
    J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
    Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
    Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Treatment Strategies for Spinal Metastases.
    Kowalchuk RO; Mullikin TC; Kim DK; Morris JM; Ebner DK; Harmsen WS; Merrell KW; Beriwal S; Waddle MR; Kim H
    Pract Radiat Oncol; 2022; 12(3):236-244. PubMed ID: 35045365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
    Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
    J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
    Bjerklund Johansen TE; Baker TM; Black LK
    BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
    Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
    Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system.
    Arruda GV; Lourenção M; de Oliveira JHC; Galendi JSC; Jacinto AA
    Lancet Reg Health Am; 2022 Oct; 14():100329. PubMed ID: 36777381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.